西妥昔单抗联合顺铂对鼻咽癌荷瘤裸鼠移植瘤生长作用的影响

目的：探讨靶向表皮生长因子受体（EGFR）特异性单抗西妥昔单抗单药及与顺铂联合应用对鼻咽癌荷瘤裸鼠移植瘤生长的影响及其可能的作用机制。方法：将鼻咽癌细胞HONE1制成细胞悬液后接种于裸鼠皮下,待成瘤后将裸鼠随机分入4个处理组：生理盐水组、西妥昔单抗组、顺铂组及两药联合组。定期测量每只裸鼠肿瘤最大径和最小径,计算肿瘤体积。用药结束后,处死裸鼠,取出肿瘤组织,称重,计算抑瘤率。用免疫组化方法检测肿瘤组织中磷酸化蛋白激酶B（p-AKT）和人磷酸化细胞外信号调节激酶（p-ERK）表达。结果：与生理盐水组相比,西妥昔单抗单药组肿瘤体积变化及治疗后平均瘤重差异均无统计学意义,顺铂单药组及两药联合组均有抑瘤效应,以两药联合组抑瘤效果尤为显著。免疫组化显示肿瘤组织AKT和ERK磷酸化水平在顺铂处理组上调,而在西妥昔单抗单药及联用组则较低。结论：西妥昔单抗单药对HONE1鼻咽癌荷瘤裸鼠移植瘤的生长无明显影响,但其与顺铂联用可增加顺铂的抑瘤作用。

Synergistic anti-tumor activity of cetuximab combining with cisplatin in human nasopharyngeal carcinoma cells

AIM： To detect the effect of cetuximab combining with cisplatin on growth effect of nasopharyngeal carcinoma xenografts in nude mice and its possible mechanism. METHODS： HONE1 cancer cells were suspended and injected into nude mice subcutaneouly. Then the mice were randomly assigned to four groups： normal saline group, cetuximab group, cisplatin group and combination group. The largest and smallest diameters of athymic mouse tumor were measured regularly, and the tumor volume was calculated. After treatment, all animals were sacrificed, the tumor xenografts were weighed and the inhibitory rates were calculated. The expression of phospho-protein kinase β （p-AKT） and phospho-extracellular signal regulated kinase （p- ERK） were detected with immunohistochemistry. RESULTS： The tumor volume and average weight of cetuximab group after treatment had no significant differentce, group and there was obvious inhibitory effect in cisplatin the combination with cetuximab group, but the later was more mistry assay showed significant. The immunohistochethat the expression levels of p-AKT and p-ERK were higher in the samples from the group treated with cisplatin alone compared with saline group, but reduced when treated with cetuximab combined with cisplatin or not. CONCLUSION： The of transplantation tumor on HONE1 nasopharyngeal carcinoma bearing cancer in nude mice had no significant effect, it could enhance the antitumor effect of cisplatin on nasopharyngeal carcinoma xenografts.